


## Data Sheet

<b>Product Name:</b>	IRAK-1-4 Inhibitor I
<b>Cat. No.:</b>	CS-0704
<b>CAS No.:</b>	509093-47-4
<b>Molecular Formula:</b>	C <sub>20</sub> H <sub>21</sub> N <sub>5</sub> O <sub>4</sub>
<b>Molecular Weight:</b>	395.41
<b>Target:</b>	IRAK
<b>Pathway:</b>	Immunology/Inflammation; Protein Tyrosine Kinase/RTK
<b>Solubility:</b>	DMSO : 14.29 mg/mL (36.14 mM; Need ultrasonic)



### BIOLOGICAL ACTIVITY:

IRAK-1-4 Inhibitor I is a dual inhibitor of **IRAK4** and **IRAK1** with **IC<sub>50</sub>** of 0.2  $\mu$ M and 0.3  $\mu$ M, respectively. **IC<sub>50</sub> & Target:** IC<sub>50</sub>: 0.2  $\mu$ M (IRAK-4), 0.3  $\mu$ M (IRAK-1)<sup>[1]</sup> **In Vitro:** IRAK-1-4 Inhibitor I has **IC<sub>50</sub>** greater than the highest concentration tested (10  $\mu$ M) against a panel of 27 other kinases, including the most closely homologous (outside of the IRAK family) Lck and pp60<sup>SRC</sup>. Additionally, IRAK-1-4 Inhibitor I does not show any signs of cytotoxicity in a 72 h proliferation assay in HeLa cells (ED<sub>50</sub>>30  $\mu$ M). Significant inhibition of IRAK-1 is observed with IRAK-1-4 Inhibitor I (IRAK-1 IC<sub>50</sub>=0.3  $\mu$ M)<sup>[1]</sup>. IRAK-1/4 inhibitor eliminates the LPS-induced increases in Bcl10, NF- $\kappa$ B, and IL-8. IRAK-1/4 mediates LPS-induced IL-8 activation and functions upstream of Bcl10. The LPS-induced increase in Bcl10 declines by 73% (from 5.18 $\pm$ 0.22 to 2.36 $\pm$ 0.08 ng/mL), and the IL-8 response decline by 60% (from 2.64 $\pm$ 0.31 to 1.14 $\pm$ 0.08 ng/mL)<sup>[2]</sup>.

### PROTOCOL (Extracted from published papers and Only for reference)

**Cell Assay:** IRAK-1-4 Inhibitor I is dissolved in DMSO and stored, and then diluted with appropriate media before use<sup>[2],[2]</sup> NCM460 cells, grown in 24-well plates, are incubated with 50  $\mu$ M IRAK-1/4 inhibitor for 2 h. After 2 h, the media are changed, and new media with or without LPS (10 ng/mL) added. Treatment is terminated at 6 h, and spent media and cells are collected for IL-8 and other assays<sup>[2]</sup>.

### References:

[1]. Powers JP, et al. Discovery and initial SAR of inhibitors of interleukin-1 receptor-associated kinase-4. *Bioorg Med Chem Lett*. 2006 Jun 1;16(11):2842-2845.

[2]. Bhattacharyya S, et al. Bcl10 mediates LPS-induced activation of NF-kappaB and IL-8 in human intestinal epithelial cells. *Am J Physiol Gastrointest Liver Physiol*. 2007 Aug;293(2):G429-37.

### CAIndexNames:

Benzamide, N-[1-[2-(4-morpholinyl)ethyl]-1H-benzimidazol-2-yl]-3-nitro-

### SMILES:

O=C(C1=CC=CC([N+])([O-])=O)C1=NC2=NC3=CC=CC=C3N2CCN4CCOCC4

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 732-484-9848

Fax: 888-484-5008

E-mail: [sales@ChemScene.com](mailto:sales@ChemScene.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA